The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, “Ramsey’s promotion to COO reflects his exceptional leadership and the critical role he has played in our Company’s ...

In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

Esteve will license the ex-U.S. rights for up to ten years and will also be receiving an option to acquire the international rights in the future. Eton will supply product to Esteve at a fixed ...

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

OncoZenge AB (publ) (“OncoZenge” or the “Company”) announces that the Company has entered into a binding agreement to partner with L. Molteni & C. dei F.lli Alitti, Società di Esercizio S.p.A ...

Thrivent Financial for Lutherans lowered its position in shares of GSK plc (NYSE:GSK – Free Report) by 6.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 49,864 shares of the ...

The signing ceremony was attended by a distinguished group of senior executives from both companies. The agreement was signed on behalf of United Pharmacies by Dr. Shalaei Taha, Chief Commercial ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

The growing burden of misinformation is a complex issue that demands a direct-to-patient channel through trusted sources. By ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company ...